Immunohistochemistry market to hit $6.46 billion by 2035

The global immunohistochemistry market is projected to grow from $3.44 billion in 2026 to $6.46 billion by 2035, driven by rising cancer cases, tighter companion-diagnostic rules and faster lab automation. Market Research Future says the shift is also being shaped by AI-enabled digital pathology and expanding use of multiplex testing across oncology.

Why it matters: - The immunohistochemistry market is moving from a niche lab workflow to a core oncology testing tool. - Demand is rising because more cancer cases require biomarker testing to classify tumors and guide targeted therapy. - Regulatory pressure is pushing hospitals and labs toward standardized, commercial-grade assays and automated platforms. - The market’s growth matters for diagnostic labs, reagent makers, instrument vendors and drug developers that rely on tissue-based testing.

What happened: - Market Research Future projects the global immunohistochemistry market will grow from $3.44 billion in 2026 to $6.46 billion by 2035. - The forecast implies a 7.25% compound annual growth rate from 2026 to 2035. - The market base was estimated at $3.21 billion in 2025. - The report frames cancer incidence, companion-diagnostic mandates and lab automation as the main growth drivers. - Request a free sample of the report. - Read the detailed report.

The details: - GLOBOCAN 2023 reported about 20 million new cancer cases worldwide, with cases projected to approach 27.5 million by 2035. - The report says each malignant tissue specimen typically requires at least one, and often four to six, IHC biomarker tests. - Companion-diagnostic requirements before targeted-therapy prescriptions are expanding across the US, EU and Japan. - The EU In Vitro Diagnostic Regulation took full effect in May 2026, raising evidence and oversight requirements for many assays. - The report says compliance costs can run from $1.2 million to $3.5 million per assay. - CMS increased reimbursement by an average 6.2% across CPT codes 88342 through 88344 in the 2025 physician fee schedule. - CAP updated its 2024 guidance to support AI-assisted grading for HER2 and PD-L1 biomarkers. - Automated slide-staining systems can process 200 or more slides per run, according to the report. - Published studies cited in the release show coefficient-of-variation reductions from 15% to 20% with manual methods to under 5% with automation. - Contract research organizations are expected to invest more than $1.8 billion in histopathology services between 2023 and 2025. - Antibodies led the product mix with about 38.6% revenue share in 2025. - Equipment is projected to reach $1.14 billion by 2035. - Software is the fastest-growing product segment, at 8.18% CAGR from 2026 to 2035. - Reagents and kits generated $0.52 billion in 2025. - Diagnostics held about 56.5% of application share in 2025. - Drug discovery and testing is the fastest-growing application segment, at 8.34% CAGR. - Indirect immunohistochemistry held about 65.5% of detection-method share in 2025. - Direct immunohistochemistry is projected to grow at 7.92% CAGR. - Hospitals and diagnostic centers held about 51.8% of end-user share in 2025. - Academic and research institutes are the fastest-growing end-user segment, at 8.38% CAGR. - Pharmaceutical and biotech companies accounted for $0.48 billion in 2025.

Between the lines: - The report points to a market that is being pulled by structural clinical demand, not optional spending. - Regulatory tightening tends to favor validated vendors with scale, which can pressure smaller reagent makers and reduce room for laboratory-developed tests. - Automation and software bundling are reshaping buying patterns, because labs want higher throughput, better reproducibility and less operator dependence. - The report also suggests AI and multiplex testing could become more important as pathology labor shortages persist. - North America remained the largest regional market in 2025, with about 37.9% share. - Asia-Pacific is the fastest-growing region, with an 8.47% CAGR from 2026 to 2035. - Europe is being shaped by IVDR enforcement, while Middle East and Africa and South America are growing from smaller bases.

What's next: - The report expects AI-driven pathology workflows to become more common by 2030. - It also forecasts broader use of end-to-end platforms that combine slide scanning, biomarker scoring and report generation. - Multiplex fluorescence testing and spatial biology are expected to gain share between 2028 and 2032. - The release says the spatial-biology instrument segment could exceed $900 million by 2032. - Manufacturers are likely to keep competing on integrated reagent, instrument and software packages.

The bottom line: - Immunohistochemistry is shifting from a basic staining market to a regulated, automated and increasingly AI-enabled diagnostics category.